礼来更新业绩指引！预计第四季度收入约为135亿美元，不及市场预期
1月14日，礼来更新2024年收入指引，预计2024年第四季度收入约为135亿美元，市场预估140亿美元；2024年预计收入约为450亿美元。
初步预计四季度Mounjaro销售额约为35亿美元，市场预估44亿美元；初步预计四季度Zepbound销售额约为19亿美元，市场预估22亿美元。
预计2025年收入将在580亿美元至610亿美元之间，市场预估为587.2亿美元；预计2025年收入增长将来自新药JAYPIRCA、EBGLYSS、OMVOH和KISUNLA。
礼来公司预计2025年销售额增长将来自新药。
预计2025年上半年可生产可销售的胰岛素剂量将比去年同期增加至少60%。
礼来盘中下跌逾7%，创11月15日以来最大盘中跌幅。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10